“In addition to sincere appreciation for the support and efforts of NNSA, I would like to recognize and thank our partners at the University of Missouri Research Reactor (MURR®) for their important contribution to the success of this project,” said Stephen Merrick, President and CEO of NorthStar Medical Radioisotopes. “As a result of this highly successful collaboration between government, academia and industry, NorthStar has reached a transformative inflection point in our mission to provide a reliable supply of Mo-99 produced without uranium to meet U.S. healthcare needs and strengthen national security. The commercial launch of the RadioGenix System is well underway, and we are ramping up expansion activities to further increase production capacity for domestically-produced Mo-99.”
The Mo-99 Topical Meeting is intended to serve as a workshop where international and domestic policy and technical experts can gather to present and discuss progress toward achieving the production of Mo-99 without the use of highly enriched uranium (HEU) in support of nonproliferation objectives and global reliability of supply.
Partial funding for NorthStar’s technology was provided by the U.S. Department of Energy’s National Nuclear Security Administration. Under provisions of the American Medical Isotopes Production Act of 2012, efforts have been made to establish domestic production of Mo-99 and to promote the use of Mo-99 produced without reliance on highly enriched uranium, which is a nuclear proliferation risk. NorthStar’s technology uses stable isotopes of molybdenum, rather than enriched uranium, thereby avoiding the national security and environmental risks associated with enriched uranium.
About the RadioGenix® System
The RadioGenix System is an innovative, high tech system that is approved for processing non-uranium/non-highly enriched uranium molybdenum-99 (Mo-99) for the production of the important medical radioisotope, technetium-99m (Tc-99m). Prior to availability of RadioGenix technology, the U.S. supply chain for Mo-99 has been subject to frequent and sometimes severe interruptions which negatively impact patient healthcare. Approved by the U.S. Food and Drug Administration in February 2018, the RadioGenix System is the first and only on-site, automated isotope separation system of its kind for use with non-uranium/non-highly enriched uranium based Mo-99.
Indication and Important Risk Information About the RadioGenix® System and Sodium Pertechnetate Tc 99m Injection USP
